Biologics and Psoriasis The Beat Goes On
Biologics and Psoriasis The Beat Goes On
复制标题
DOI：
10.1016/j.det.2018.07.004
复制
发表时间：
2019-01-01
影响因子：
2.4
通讯作者：
Lebwohl, Mark G.
中科院分区：
文献类型：
--
作者：
Kim, Hee J.;Lebwohl, Mark G.
银屑病是一种慢性、免疫介导的炎症性皮肤病，需要长期治疗以控制疾病。本文回顾了临床试验中的数据，以评估和比较目前批准用于治疗牛皮癣的生物制剂的各种特性。本文研究的生物制剂的属性包括疗效、长期维持、总体安全性、起效的中位时间、体重调整、注射频率、银屑病关节炎的适应症以及妊娠安全性。在这里，我们评估生物治疗的理想选择可能是银屑病患者的特定需求。
Psoriasis is a chronic, immune-mediated, inflammatory skin disease that requires long-term therapy for disease control. This article reviews data presented in clinical trials to evaluate and compare various characteristics of biologics that are currently approved for the treatment of psoriasis. Attributes of biological agents that are examined in this article include efficacy, long-term maintenance, overall safety, median time to onset of efficacy, adjustment for body weight, frequency of injections, indication for psoriatic arthritis, and safety in pregnancy. Here, we evaluate what the ideal choice of biological therapy may be for psoriasis patients with specific needs.